Innophore uses cavity-first computational discovery and structure-guided engineering to identify and optimise enzymes for industrial biocatalysis.
The method focuses on the active-site cavity—the 3D environment responsible for catalysis, rather than sequence similarity alone. Catalophore™ point-cloud technology helps identify candidates with suitable activity, substrate scope, selectivity, stability, and process compatibility.
Innophore’s methods are used in industrial biotechnology engagements and supported by more than ten years of peer-reviewed biocatalysis publications. The core cavity point-cloud method is protected by granted patents.
The methods cover oxidoreductases, transferases, hydrolases, lyases, and ligases, with additional work on polymerases. The platform delivers ranked candidates and variant hypotheses for experimental follow-up. Final performance must be validated under relevant process conditions.
Deliverables may include ranked candidates with structural rationale, structural files, active-site models, mutation lists, and reports. Customers retain IP rights to enzymes and variants delivered through an engagement.
Innophore GmbH is a biotechnology company that provides a platform for enzyme and drug discovery through its proprietary Catalophore technology. Founded in 2017 in Graz, Austria, the company uses artificial intelligence and 3D point-cloud analysis to characterize protein binding sites rather than focusing on proteins alone. This methodology allows the company to conduct cavity-based searches across entire proteomes, offering capabilities that exceed traditional sequence or fold comparison methods. By transforming molecular structure into actionable data, Innophore supports research and development pipelines by identifying and optimizing protein candidates for applications in biotechnology, pharmaceuticals, and industrial processes.
The company's technology is utilized by global partners in sectors including healthcare, chemicals, and consumer products to accelerate R&D and improve safety. Innophore’s solutions enable clients to detect potential off-target interactions, reduce side effects, and optimize therapeutic or industrial enzymes more efficiently. The company gained significant industry recognition during the COVID-19 pandemic by rapidly identifying the SARS-CoV-2 main protease as a drug target. Innophore maintains collaborations with major technology partners, such as NVIDIA, to leverage advanced computational platforms like BioNeMo for large-scale structural modeling and drug discovery predictions, helping clients bring products to market with greater speed and precision.